Medication info
Rosuvastatin/valsartan tablet 20/80 milligrams

Rosuvastatin/valsartan tablet 20/80 milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Hankook Hyutech Pharmaceutical Co., Ltd.
Appearance
Brown round film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202003914 · Approved 2020.05.27 · Insurance code 649104930

Summary

Main use
Improvement of dyslipidemia; treatment of hypertension and heart failure; prevention of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medication is intended for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medication be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medication once daily; the dose should not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. However, do not administer this medication to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hankook Hyutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; treatment of hypertension and heart failure; prevention of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
View approved original text

This medication is used for patients who need to receive both valsartan and rosuvastatin together. Valsartan is primarily used to reduce the risk of death in patients with essential hypertension, heart failure, and left ventricular dysfunction following myocardial infarction. It is particularly useful for heart failure patients intolerant to ACE inhibitors. Rosuvastatin is used as an adjunct when dietary measures are insufficient to control hypercholesterolemia and dyslipidemia, and it helps delay the progression of atherosclerosis. It is also effective in reducing the risk of cardiovascular diseases, lowering the risk of stroke and myocardial infarction, and reducing the risk of arterial revascularization procedures. Therefore, this medication is used to improve cardiovascular health in patients with both hypertension and dyslipidemia.

How to take

Adult dose

This medication is intended for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medication be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medication once daily; the dose should not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. However, do not administer this medication to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication may cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Women of childbearing potential should use appropriate contraceptive methods, and it is safe for pregnant or lactating women not to take this medication. Patients with severely impaired liver or kidney function, muscle diseases, or specific allergy histories should not take this medication. Caution should be exercised for elderly patients or those with hyperkalemia, and patients with mild liver impairment should be closely monitored while on this medication. This medication may cause muscle-related side effects such as myalgia, myopathy, and, rarely, rhabdomyolysis, so patients experiencing muscle pain or weakness should consult a physician immediately. Additionally, symptoms of liver function abnormalities, allergic reactions, and hypotension should be carefully monitored. Interactions may occur when taken with other medications, so patients should inform their healthcare provider of any concurrent medications. In cases of overdose, there is no specific antidote, so patients should seek appropriate treatment at a medical facility immediately. This medication should be stored out of reach of children, and it is safe not to transfer it to other containers. If any unusual symptoms occur during use, patients should immediately consult their healthcare provider for appropriate action.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum aminotransferase levels (AST, ALT), increased serum creatinine phosphokinase, increased serum potassium, elevated gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like conditions, herpes zoster, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood glucose, increased triglycerides, elevated blood pressure, hypertension exacerbation, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified skin inflammation, localized skin reaction, palpitations, angina exacerbation, auditory abnormalities, overactive bladder, increased serum creatinine, vitreous detachment, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, back pain (low back pain), abdominal pain, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, drowsiness, atrial fibrillation, loss of appetite, lethargy, vascular edema, erythema, pruritus, serum sickness, vasculitis, hepatitis, syncope, nasal bleeding, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased hematocrit, decreased hemoglobin, edema, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, myasthenia gravis, oculobulbar myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not let light in. It is best to store it at room temperature, between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

Brown round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.